CLEAR Care Companion Application

Status Recruiting

Clinical Trial Summary

Hospital readmissions are common after major cancer surgery, leading to poorer patient outcomes, increased mortality and additional costs. In this study, Clinical and Engineering Approaches to Readmission (CLEAR) Care Companion Application, investigators aim to utilize a smartphone application that tracks concerning postoperative symptoms and provides educational interventions to determine if this can minimize delays in communication between patients and medical providers, increase patient satisfaction with the care received, and reduce or lessen the severity of readmissions.

Clinical Trial Description

Patients complete clinically meaningful questions and validated questionnaires pertaining to physiological and psychological symptoms that serve as early indicators of readmission, with the aim to improve experience by empowering patient to be active participants in their recovery, identify complications early to minimize morbidity and reduce overall readmissions. The study has the following three objectives: (1) Assess patient engagement with the CLEAR Care Companion application for patients that have undergone radical cystectomy (2) Measure patient experience with the application and its effect on satisfaction with overall care (3) Evaluate the effect of the application on case complexity (readmission intensity) and overall readmission rates. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05578898
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Recruiting
Phase	N/A
Start date	August 12, 2022
Completion date	August 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06034015` - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers	Phase 1
Recruiting	`NCT04235764` - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed	`NCT02371447` - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer	Phase 1/Phase 2
Recruiting	`NCT04081246` - Transurethral Modified En Bloc Resection For Large Bladder Tumours.	N/A
Recruiting	`NCT06059547` - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer	Phase 2
Terminated	`NCT04779489` - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer	N/A
Not yet recruiting	`NCT04493489` - Propranolol Adjuvant Treatment of Bladder Cancer	Phase 2
Completed	`NCT03520231` - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases	Phase 2
Recruiting	`NCT04537221` - Nordic Cystectomy Study III - Transfusion
Withdrawn	`NCT03007771` - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia	Phase 1
Completed	`NCT01955408` - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment	N/A
Completed	`NCT04487457` - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting	`NCT04383210` - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors	Phase 2
Recruiting	`NCT05562791` - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer	Phase 1
Completed	`NCT00199849` - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine	Phase 1
Completed	`NCT02781428` - To Detect the Sensitivity of the UroMark Assay
Recruiting	`NCT04738630` - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer	Phase 2
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Active, not recruiting	`NCT03978624` - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer	Phase 2
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A